A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Conditions:   VHL - Von Hippel-Lindau Syndrome;   VHL;   VHL Gene Mutation;   VHL Syndrome;   VHL Gene Inactivation;   VHL-Associated Renal Cell Carcinoma;   VHL-Associated Clear Cell Renal Cell Carcinoma Intervention:   Drug: PT2977 Sponsor:   Peloton Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials